Cite
144P Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer (TD-NICE): A single arm, phase II study.
MLA
Yan, X., et al. “144P Tislelizumab Combined with Chemotherapy as Neoadjuvant Therapy for Surgically Resectable Esophageal Cancer (TD-NICE): A Single Arm, Phase II Study.” Annals of Oncology, vol. 32, Dec. 2021, p. S1442. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.10.163.
APA
Yan, X., Zhao, J., Lei, J., Duan, H., Ni, Y., Zhou, Y., Wang, X., Qi, H., Liu, H., Tian, F., Lu, Q., Sun, J., Yang, E., Zhong, D., Wang, T., Huang, L., Wang, J., & Jiang, T. (2021). 144P Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer (TD-NICE): A single arm, phase II study. Annals of Oncology, 32, S1442. https://doi.org/10.1016/j.annonc.2021.10.163
Chicago
Yan, X., J. Zhao, J. Lei, H. Duan, Y. Ni, Y. Zhou, X. Wang, et al. 2021. “144P Tislelizumab Combined with Chemotherapy as Neoadjuvant Therapy for Surgically Resectable Esophageal Cancer (TD-NICE): A Single Arm, Phase II Study.” Annals of Oncology 32 (December): S1442. doi:10.1016/j.annonc.2021.10.163.